Back to results
US 2016/0354347 A1Published application
Nuclear Transport Modulators and Uses Thereof
AssigneeKaryopharm Therapeutics Inc.
InventorsVincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
Claims20
A method for treating a disorder associated with CRM1 activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by structural formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from hydrogen and C1-C4 alkyl;
- R2 is selected from O and S;
- and
- R3 is selected from —N(R4)—(C3-C6 cycloalkyl), —C1-C6 alkyl, —(C0-C4 alkylene)-heterocyclyl, and —(C0-C4 alkylene)-heteroaryl, wherein any alkyl, alkylene, heterocyclyl, and heteroaryl portion of R3 is optionally and independently substituted;
- and
- R4 is selected from hydrogen and C1-C4 alkyl, and
- wherein, the disorder is selected from lupus, multiple sclerosis, amyotrophic lateral sclerosis and rheumatoid arthritis.
5 more elements
19-31. (canceled)
Dependencies are inferred from the claim text.